Figure 2.

Subject H0018. (a) HIV viral load (copies/ml plasma, □) and CD4⁺ T-cell count (per microlitre of whole blood, ▪). H0018 was asymptomatic until HSV retinitis immediately before commencing HAART with stavudine, lamivudine and nevirapine on 25/9/98, then changed stavudine for zidovudine on 25/10/00 because of a mild neuropathy. (b) LDA frequencies of CD8⁺ CTLp specific for pp65 peptides 69 and 56. (c, f) Selective expansion in the proportion of pp65 peptide 56-specific clonotype 18D sequence (○) within all Vβ6.4⁺ sequences in PBMC and in CD28^– PBMC following HAART, with stable maintenance of clonotype 18B (•) (d) Progressive contraction in the clone size (expressed as cells of the clone/10⁶ CD8⁺ T cells) of gag peptide 703.3 specific clonotype 18A following HAART (⋄). The calculated half-life of decline was 51 weeks. The LDA frequency of CTLp specific for this peptide remained stable (◊). (e, g) Progressive contraction in the proportion of clonotype 18A sequences within all Vβ13.1⁺ sequences in PBMC and in CD28^– PBMC following HAART (•; used to calculate clone size data in d). Contraction in the proportion of gag peptide 7027-specific clonotype 18E sequences within all Vα6⁺ sequences in PBMC and in CD28^– PBMC following HAART (○).